Zimbabwe sees serious drug shortages, as NatPharm fails to meet demand

14 November 2013

A serious shortage of life-saving clinical drugs is having an adverse effect on the health sector in Zimbabwe, according to a senior official in the Ministry of Health, putting the country's disaster preparedness in limbo.

The daily Newsday newspaper reported this week that funding for essential medicines and medical supplies is falling short of requirements as the National Pharmaceutical Company of Zimbabwe (NatPharm) was unable to meet demand. NatPharm was set up to store and distribute drugs, but cannot carry out the procurement function because of its lack of funding.

Government owes NatPharm $11 million

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK